Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035603 | 0.86 | ADORA2B (0.55) | PNPADORA2BXDHKMT2ADAO | |
| SCHEMBL13735423 | 0.79 | KMT2A (0.45) | PNPADORA2BXDHKMT2AMAPT | |
| SCHEMBL5677631 | 0.79 | PNP (0.80) | PNPKMT2ADAORNASEH1GAA | |
| SCHEMBL985622 | 0.77 | ADORA2B (0.51) | ADORA2BXDHKMT2AMAPT | |
| SCHEMBL31336166 | 0.77 | ADORA2B (0.51) | PNPADORA2BXDHKMT2ARNASEH1 | |
| Hydrochloric Acid SCHEMBL8649625 | 0.76 | VNN1 (0.42) | PNPADORA2BKMT2AGAAMAPT | |
| SCHEMBL3433598 | 0.75 | PNP (0.68) | PNPXDHKMT2APKM | |
| SCHEMBL3304711 | 0.74 | PNP (0.60) | PNPADORA2BXDHKMT2APKM | |
| SCHEMBL9172603 | 0.73 | XDH (0.45) | PNPADORA2BXDHDAORNASEH1 | |
| SCHEMBL380136 | 0.73 | MAPT (0.48) | ADORA2BXDHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | claimed |
| US-20020013299-A1 | Substituted O6-benzyl-8-aza-guanines | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-01-31 | — | — | US | claimed |
| EP-1142893-A1 | Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2001-10-10 | — | — | EP | claimed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | claimed |
| CN-102993203-A | Preparation of 8-benzyl xanthine derivative and application | WENZHOU MEDICAL COLLEGE | 2013-03-27 | — | — | CN | disclosed |
| CN-102993203-A | Preparation of 8-benzyl xanthine derivative and application | WENZHOU MEDICAL COLLEGE | 2013-03-27 | — | — | CN | disclosed |
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1372411-A1 | LOW GLYCEMIC RESPONSE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1322184-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1322185-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1289510-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001093847-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093831-A2 | LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-0775142-B1 | SUBSTITUTED O6 -BENZYLGUANINES | US HEALTH (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6303604-B1 | USED AS ANTINEOPLASTIC ALKYLATING AGENT WHICH CAUSES CYTOTOXIC LESIONS AT THE O.SUP.6-POSITION OF QUANINE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-16 | — | — | US | disclosed |
| EP-1142893-A1 | Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6172070-B1 | IN POLYOXYETHYLENE GLYCOL CARRIER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-01-09 | — | — | US | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013299-A1 | Substituted O6-benzyl-8-aza-guanines | OGG1, UNG, AGT | PNP 60/4885ADORA2B 1358/4885XDH 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.